Alvotech SDB

Research Alvotech SDB (ALVO-SDB) on Bullrun: market cap SEK 12.62B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerALVO-SDB
• ExchangeST
• CountryLuxembourg
• SectorHealthcare
• IndustryDrug Manufacturers - Specialty & Generic
• CurrencySEK
• Market capSEK 12.62B
• Financial periodQ4 2025
• RevenueSEK 166.57M
• Net income-SEK 108.55M
• Free cash flow-SEK 78.68M
• Gross margin63.2%

Valuation Snapshot

latest market cap is SEK 12.62B.

About Alvotech SDB

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications;

Frequently asked questions

What is Alvotech SDB's market cap?

Alvotech SDB's market capitalization is SEK 12.62B.

What does Alvotech SDB do?

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.